Innovación en Cirugía, Trasplante y Tecnologías para la Salud » Investigación en Hepatología, Cirugía Hepatobiliar y Trasplante Hepático
Coordinador de Grupo
Andres Valdivieso López
Doctor en Medicina
Jefe de Sección Cirugia General en el HUC
Profesor Titular / Agregado en la Unidad Docente Fac. Medicina y Odontologia en Cruces Dpto. Cirugia, Radiologia y Medicina Fisica - UPV/EHU
Hospital Universitario Cruces
Contacto
(0034) 94 600 6000
Miembros del Grupo
Francisco Javier Bustamante Schneider
José Ramón Fernández Ramos
Miguel Angel Gastaca Mateo
Cesar Ibarra Ponce de Leon
Ariane Imaz Ayo
Emma Martínez Moneo
Ibone Palomares Etxeberria
Mikel Prieto Calvo
Patricia Ruiz Ordorica
Patricia Salvador Bengoechea
María Senosiain Labiano
María Jesús Suarez Regueiro
Milagros Testillano Tarrero
Alberto Ventoso Castiñeira
Líneas de Investigación
Hepatocarcinoma.
Metabolómica.
Esteatosis.
Inmunosupresión en trasplante hepático.
Eficacia del trasplante hepático en indicaciones límites.
Donantes en el trasplante hepático.
Marcadores tumorales en metástasis hepáticas de carcinoma colorectal.
Actividades del Grupo

Marcadores metabolómicos en la evaluación de la respuesta al sorafenib en los pacientes con hepatocarcinoma avanzado.

Desde 2007 los pacientes con hepatocarcinoma avanzado y buena función hepática son tratados con sorafenib, un inhibidor de tirosinkinasa que ha demostrado aumentar la supervivencia. Sin embargo, debido a su mecanismo de acción, los criterios radiológicos convencionales no son útiles para evaluar la respuesta al tratamiento con sorafenib. Teniendo en cuenta que se trata de un fármaco con un modesto beneficio de supervivencia, efectos adversos relevantes y alto coste sería importante disponer de algún marcador biológico para evaluar la respuesta terapéutica. Debido a su mecanismo de acción antiproliferativo y antiangiogénico es posible que la metabolómica, por su capacidad para identificar miles de moléculas que reflejan procesos intracelulares, pueda identificar algún marcador pronóstico y/o de respuesta.

Validación clínica de un test no invasivo para el diagnostico diferencial precoz entre esteatosis simple y esteatohepatitis.

 

Respecto a la inmunosupresión en el trasplante hepático, nuestra actividad se centra en:

  • Estudio de eficacia-seguridad de fármacos inmunosupresores en el trasplante hepático. En este campo participamos en estudios multicéntricos en Fase II y III de nuevos fármacos inmunosupresores.
  • Desarrollo de un modelo farmacocinético poblacional que permita una mejor dosificación del fármaco inmunosupresor principal (tacrolimus), con mayor eficacia y con los menores efectos secundarios, en colaboración con el Grupo de Farmacocinética Clínica del Departamento de Farmacología de la Universidad del País Vasco.
  • Estudio de los distintos polimorfismos genéticos de enzimas metabolizadores (fundamentalmente CYP y p-glicoproteina) en el hígado y en el intestino, que podrían determinar cambios en la eficacia y toxicidad del tacrolimus, en colaboración con Dynakin, Progenika y el Grupo de Farmacocinética Clínica del Departamento de Farmacología de la Universidad del País Vasco.

Por otro lado, participamos en estudios multicéntricos para evaluar la eficacia del trasplante hepático en indicaciones límite, tales como VIH, tumores hepáticos y en estudios sobre factores de riesgo del donante y en un modelo de asignación donante –receptor con criterios expandidos.

Respecto a la cirugía hepatobiliar, estamos realizando estudios de marcadores tumorales en metástasis hepáticas de carcinoma colorectal en colaboración con Pharmakine y BIOEF.

 

 

Publicaciones Científicas

Adam R, Karam V, Cailliez V, Grady JGO, Mirza D, Cherqui D, et al. 2018 Annual Report of the European Liver Transplant Registry (ELTR)-50-year evolution of liver transplantation. Transpl. Int. 2018; 31(12): 1293 - 1317. FI: 3,196(Q1). DOI: 10.1111/tri.13358.

Perfecto-Valeroa A, Gastaca-Mateo MA, Prieto-Calvo M, Ortiz-de Urbina J, Valdivieso-Lopez A. Biliary cyst of the cystic duct: A case of Todani type VI. Cir Esp. 2018; 96(10): 658 - 660. FI: 0,841(Q4). DOI: 10.1016/j.ciresp.2018.04.013. EDITORIAL MATERIAL.

Fernández-Gomez L, Prieto-Calvo M, Alonso-Calderon E, Larrea-Oleaga J, Marquina-Tobalina T. Conservative Management of Massive Pneumoperitoneum After Argon Plasma Coagulation. Cir Esp. 2018; 96(1): 56 - 58. FI: 0,841(Q4). EDITORIAL MATERIAL.

Perez-Gonzalez C, Alosno-Calderon E, Sarriugarte-Lasarte A, Mifsut-Porcel P, Prieto-Calvo M. De Garengeot's hernia: report of two cases of this rare entity. Rev. Hispanoam. Hernia. 2018; 6(3): 141 - 144. FI: (Q). DOI: 10.20960/rhh.130.

Manzardo C, Londono MC, Castells L, Testillano M, Montero JL, Penafiel J, et al. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study. Am. J. Transplant. 2018; 18(10): 2513 - 2522. FI: 6,493(Q1). DOI: 10.1111/ajt.14996.

Moran RA, Garcia-Rayado G, de la Iglesia-Garcia D, Martinez-Moneo E, Fort-Martorell E, Lauret-Brana E, et al. Influence of age, body mass index and comorbidity on major outcomes in acute pancreatitis, a prospective nation-wide multicentre study. United Eur. Gastroenterol. J. 2018; 6(10): 1508 - 1518. FI: 3,477(Q2). DOI: 10.1177/2050640618798155.

Gastaca M, Bruno M, Ruiz P, Ventoso A, Palomares I, Prieto M, et al. Liver transplantation in patients with espontaneous spleno-renal shunt. Transplantation. 2018; 102(5): 175 - 176. MEETING ABSTRACT.

Gastaca M, Bruno M, Ruiz P, Ventoso A, Palomares I, Prieto M, et al. Liver Transplantation in Patients with Spontaneous Spleno-Renal Shunt. Am. J. Transplant. 2018; 18: 559 - 559. MEETING ABSTRACT

Gastaca M, Bustamante J, Ventoso A, Fernandez JR, Ruiz P, Palomares I, et al. Long-term outcomes of liver transplantation in patients with pre-transplant renal dysfunction treated with induction therapy and delayed reduced de novo once-daily tacrolimus. Transplantation. 2018; 102(5): 247 - 247. MEETING ABSTRACT.

Gastaca M, Bustamante J, Ventoso A, Fernandez J, Ruiz P, Testillano M, et al. Long-Term Outcomes of Liver Transplantation in Patients with Pre-Transplant Renal Dysfunction Treated with Induction Therapy and Delayed Reduced De Novo Once-Daily Tacrolimus. Am. J. Transplant .2018; 18: 838 - 838. MEETING ABSTRACT

Lapitz A, Arbelaiz A, Azkargorta M, Krawczyk M, Santos-Laso A, Perugorria MJ, et al. Novel protein biomarkers in serum extracellular vesicles for the diagnosis of primary sclerosing cholangitis (PSC) in patients with ulcerative colitis (UC). J Hepatol. 2018; 68: 220 - 220. MEETING ABSTRACT.

Herrero JI, Cuervas-Mons V, Gomez-Bravo MA, Fabregat J, Otero A, Bilbao I, et al. Prevalence and progression of chronic kidney disease after liver transplant: a prospective, real-life, observational, two-year multicenter study. Rev. Esp. Enferm. Dig. 2018; 110(9): 538 - 543. FI: 1,632(Q4). DOI: 10.17235/reed.2018.5431/2017.

Sallinen VJ, Le Large TTY, Tieftrunk E, Galeev S, Kovalenko Z, Haugvik SP, et al. Prognosis of sporadic resected small (<= 2 cm) nonfunctional pancreatic neuroendocrine tumors - a multi-institutional study. HPB. 2018; 20(3): 251 - 259. FI: 3,131(Q1). DOI: 10.1016/j.hpb.2017.08.034.

Arbelaiz A, Lapitz A, Krawczyk M, Santos-Laso A, Lavin JL, Perugorria MJ, et al. Serum and urine extracellular vesicles contain mRNA biomarkers for primary sclerosing cholangitis (PSC) and cholangiocarcinoma (CCA). J Hepatol. 2018; 68: 435 - 435. MEETING ABSTRACT.

Gastaca M, Prieto M, Palomares I, Valdivieso A. Significance of measured intraoperative portal vein flows after thrombendvenectomy in deceased donor liver transplantations with portal vein thrombosis. Liver Transplant. 2018; 24(4): 565 - 566. FI: 3,752(Q1). DOI: 10.1002/lt.24996. LETTER.

Hessheimer A, Coll E, Valdivieso A, Gomez M, Santoyo J, Ramirez P, et al. Superior Outcomes Using Normothermic Regional Perfusion in CDCD Liver Transplantation. Transplantation. 2018; 102(7): 380 - 380. MEETING ABSTRACT.

Hessheimer A, Coll E, Valdivieso A, Gomez M, Santoyo J, Ramirez P, et al. Superior outcomes using normothermic regional perfusion in cDCD liver transplantation. Transplantation. 2018; 102(5): 6 - 6. MEETING ABSTRACT.

Stigliano S, Waldthaler A, Martinez-Moneo E, Lionetto L, Robinson S, Malvik M, et al. Vitamins D and K as Factors Associated with Osteopathy in Chronic Pancreatitis: A Prospective Multicentre Study (P-BONE Study). Clin Transl Gastroenterol. 2018; 9: 197. FI: 4,621(Q1). DOI: 10.1038/s41424-018-0066-8.

Agüero F, Forner A, Valdivieso A, Blanes M, Barcena R, Manzardo C, et al. Human immunodeficiency virus-infected liver transplant recipients with incidental hepatocellular carcinoma: A prospective multicenter nationwide cohort study. Liver Transplant. 2017;23:645651. FI:3,910(Q1). DOI:10.1002/lt.24741.

Alonso-Calderón E, Pérez-González C, Prieto-Calvo M, Marquina-Tobalina T. Emphysematous pancreatitis. Fulminant course. Cir Esp. 2017;95:611. FI:1,276(Q3). DOI:10.1016/j.ciresp.2016.12.012. EDITORIAL MATERIAL

D'Avola D, Cuervas-Mons V, Martí J, Ortiz de Urbina J, Lladó L, Jimenez C, et al. Cardiovascular morbidity and mortality after liver transplantation: The protective role of mycophenolate mofetil. Liver Transplant. 2017;23:498-509. FI:3,910(Q1). DOI:10.1002/lt.24738.

Fernández Gómez-Cruzado L, Prieto Calvo M, Pérez González C, Larrea Oleaga J. Diverticulitis of the appendix as debut of appendicular cystadenoma and carcinoid tumor. Rev Esp Enferm Dig. 2017;109:145-6. FI:1,401(Q4).

Gastaca M, Sapisochin G. Mixed hepatocellular and cholangiocarcinoma: the difficulty of finding the right answer. HPB. 2017;19:558. FI:3,290(Q1). DOI:10.1016/j.hpb.2017.01.007.

Londono MC, Manzardo C, Del Campo S, Castells L, Aguilera V, Fernandez JR, et al. Interferon-free therapy is effective and safe for hepatitis C recurrence in liver transplant hepatitis C virus/human immunodeficiency virus coinfected recipients: a case-control study. J Hepatol. 2017;66:189. FI:12,486(Q1). DOI:10.1016/S0168-8278(17)30669-4. ABSTRACT

Pascasio JM, Vinaixa C, Ferrer MT, Colmenero J, Rubin A, Castells L, et al. Clinical outcomes of patients delisted from thewaiting list of liver; transplantation after interferon-free antiviral therapy. J Hepatol. 2017;66:186. FI:12,486(Q1). DOI:10.1016/S0168-8278(17)30661-X. ABSTRACT

Pascasio JM, Vinaixa C, Ferrer MT, Colmenero J, Rubin A, Castells L, et al. Clinical outcomes of patients undergoing antiviral therapy while; awaiting liver transplantation. J Hepatol. 2017;67:1168-76. FI:12,486(Q1). DOI:10.1016/j.jhep.2017.08.008.

Perelló C, Carrión JA, Ruiz-Antorán B, Crespo J, Turnes J, Llaneras J, et al. Effectiveness and safety of ombitasvir, paritaprevir, ritonavir +/- dasabuvir +/- ribavirin: An early access programme for Spanish patients; with genotype 1/4 chronic hepatitis C virus infection. J Viral Hepatitis. 2017;24:26-37. FI:4,122(Q1). DOI:10.1111/jvh.12637.

Prieto M, Gastaca M, Valdivieso A, de Urbina JO. Does Low Hepatic Artery Flow Increase Rate of Biliary Strictures in Deceased Donor Liver Transplantation? Reply Transplantation. 2017;101:311. FI:3,678(Q1). DOI:10.1097/TP.0000000000001855.

Prieto M, Gastaca M, Valdivieso A, de Urbina JO. Does Low Hepatic Artery Flow Increase Rate of Biliary Strictures in Deceased Donor Liver Transplantation? Transplantation. 2017;101:311. FI:3,678(Q1). DOI:10.1097/TP.0000000000001854.

Salcedo M, Prieto M, Castells L, Pascasio JM, Alvarez JLM, Fernandez I, et al. Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multicenter cohort study. Transpl Int. 2017;30:1041-50. FI:3,079(Q1). DOI:10.1111/tri.12999.

Agüero F, Forner A, Manzardo C, Valdivieso A, Blanes M, Barcena R, et al; FIPSE Investigators. Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma.Hepatology. 2016;63:488-98. FI:13,246(Q1). DOI:10.1002/hep.28321.

Agüero F, Rimola A, Stock P, Grossi P, Rockstroh JK, Agarwal K,et al;FIPSE/NIH HIVTR/NEAT023 Investigators. Liver Retransplantation in Patients With HIV-1 Infection: An International Multicenter Cohort Study. Am J Transplant. 2016;16:679-87. FI:6,165(Q1). DOI:10.1111/ajt.13461.

Cepedal LF, Calvo MP, Ortega HM, Lasarte AS, González CP, Val JF, et al. Glove port, how do we do it? A low-cost alternative to the single-port approach. Surg Endosc. 2016;30:5136-7. FI:3,747(Q1). DOI:10.1007/s00464-016-4820-2.

Chiche L, David A, Adam R, Oliverius MM, Klempnauer J, Vibert E, et al. Liver transplantation for adenomatosis: European experience. Liver Transpl. 2016;22:516-26. FI:3,910(Q1). DOI:10.1002/lt.24417.

Crespo J, Calleja JL, Sacristan B, Ruiz-Antoran B, Ampuero J, Garcia-Samaniego J, et al. Effectiveness And Safety Of Ombitasvir, Paritaprevir/Ritonavir And Sofosfuvir/Ledipasvir In Patients With Genotype 4 Chronic Hepatitis C Virus Infection:Results From The Spanish Real World Cohort. Hepatology. 2016;64:486-7. FI:13,246(Q1). ABSTRACT

De la Torre MA, Buades-Mateu J, de la Rosa PA, Lué A, Bustamante FJ, Serrano MT, et al. A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib. Liver Int. 2016;36:1206-12. FI:4,116(Q1). DOI:10.1111/liv.13098.

Gastaca M, Bilbao I, Jimenez M, Bustamante J, Dopazo C, Gonzalez R, et al. Safety and Efficacy of Early Everolimus When Calcineurin Inhibitors Are Not Recommended in Orthotopic Liver Transplantation. Transplant Proc. 2016;48:2506-9. FI:0,908(Q4). DOI:10.1016/j.transproceed.2016.08.027.

Gastaca M, Guerra M, Alvarez Martinez L, Ruiz P, Ventoso A, Palomares I, et al. Octogenarian Donors in Liver Transplantation. Transplant Proc. 2016;48:2856-8. FI:0,908(Q4). DOI:10.1016/j.transproceed.2016.06.063.

Gastaca M, Guerra M, Ruiz P, Ventoso A, Valdivieso A, Ortiz de Urbina J. Risk analysis of ischemic-type biliary lesions after liver transplant using octogenarian donors. Liver Transpl. 2016;22:1443-4. FI:3,910(Q1). DOI:10.1002/lt.24497.

Gastaca M, Prieto M, Valdivieso A, Ruiz P, Ventoso A, Palomares I, et al. Intraoperative Portal Flow of Less Than 1 Liter per Minute After Orthotopic Liver Transplantation Is Not Associated Per Se With an Increased Rate of Early Graft Dysfunction. Transplant Proc. 2016;48:2495-8. FI:0,908(Q4). DOI:10.1016/j.transproceed.2016.08.028.

Gastaca M, Valdivieso A, Bustamante J, Fernández JR, Ruiz P, Ventoso A, et al. Favorable longterm outcomes of liver transplant recipients treated de novo with once-daily tacrolimus: Results of a single-center cohort. Liver Transpl. 2016;22:1391-400. FI:3,910(Q1). DOI:10.1002/lt.24514.

Gastaca M, Valdivieso A, Bustamante J, Ruiz P, Fernandez J, Ventos, A, et al. Early Tacrolimus Exposure in Patients Treated De Novo with Once-Daily Tacrolimus After Liver Transplantation:Relationship with Acute Rejection and Long-Term Outcome. Am J Transplant. 2016;16:755. FI:6,165(Q1). ABSTRACT

Martínez-Moneo E, Fernández Laso AB. Pancreatitis aguda secundaria a malformación arteriovenosa. Gastroenterol Hepatol. 2016;39:276-7. FI:0,917(Q4). DOI:10.1016/j.gastrohep.2015.03.008.

Martínez-Moneo E, Stigliano S, Hedström A, Kaczka A, Malvik M, Waldthaler A, et al. Deficiency of fat-soluble vitamins in chronic pancreatitis: A systematic review and meta-analysis.Pancreatology. 2016;16:988-94. FI:2,724(Q3). DOI:10.1016/j.pan.2016.09.008.

Prieto M, Gastaca M, Agirre L, Colina A. The Comparison of Self-gripping Mesh and Sutured Mesh in Open Inguinal Hernia Repair: The Results of Meta-analysis. Ann Surg. 2016;263:e30-1. FI:8,980(Q1). DOI:10.1097/SLA.0000000000000989.

Ruiz P, Gastaca M, Valdivieso A, Ventoso A, Palomares I, Prieto M, et al. Pre-mortem cannulation and NECMO preservation for DCD liver transplantation. Am J Transpl.2016;16:585. FI:6,165(Q1). ABSTRACT

Sanchez Antolin G, Testillano M, Pascasio JM, Narvaez Rodriguez I, Prieto M, Otero A, et al; Spanish Society of Liver Transplantation Study Group Collaborating Group. Efficacy and Safety of Therapy With Simeprevir and Sofosbuvir in Liver Transplant Recipients Infected by Hepatitis C Virus Genotype 4: Cohort Spanish Society of Liver Transplantation Cohort. Transplant Proc. 2016;48:3013-6. FI:0,908(Q4). DOI:10.1016/j.transproceed.2016.08.034. ABSTRACT

Sanchez-Antolin G, Testillano M, Prieto M, Fernandez I, Xiol X, Londono MC, et al. Efficacy and safety treating the recurrent hepatitis C post-liver transplantation with Simeprevir and sofosbuvir: The Spanish experience(SETH). Hepatology. 2016;64:113. FI:13,246(Q1).

Servide JM, Prieto M, Marquina T. A rare late complication after CPRE:subcapsular liver hematoma. Rev Esp Enferm Dig. 2016;108:234-5. FI:1,401(Q4).

Agueero F, Forner A, Manzardo C, Valdivieso A, Blanes M, Barcena R, et al. The HIV infection does not have impact on survival and tumor recurrence in hepatocellular carcinoma patients treated by liver transplantation. J Hepatol. 2015;62:301. FI:10,590(Q1). ABSTRACT

Bilbao I, Salcedo M, Gomez MA, Jimenez C, Castroagudin J, Fabregat J, et al. Renal function improvement in liver transplant recipients after early everolimus conversion: A clinical practice cohort study in Spain. Liver Transplant. 2015;21:1056-1065. FI:3,951(Q1). DOI:10.1002/lt.24172.

Bustamante J, Senosian M, Valdivieso A, Fernandez JR, Gastaca M, Salvador P, et al. Management of Hepatocellular Carcinoma Recurrence After Liver Transplantation. Transplantation. 2015;99:159. FI:3,690(Q1). ABSTRACT

Buti M, Morillas RM, Perez J, Prieto M, Sola R, Palau A, et al. Entecavir has high efficacy and safety in white patients with chronic hepatitis B and comorbidities. Eur J Gastroen Hepat. 2015;27:46-54. FI:2,093(Q3). DOI:10.1097/MEG.0000000000000195.

Castells Ll, Rimola A, Manzardo C, Valdivieso A, Montero JL, Barcena R, et al. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: A prospective cohort study. J Hepatol. 2015;62:92-100. FI:10,590(Q1). DOI:10.1016/j.jhep.2014.07.034.

Cuervas-Mons V, de la Rosa G, Pardo F, San Juan F, Valdivieso A. Representacion Registro Espanol Tr. Activity and results of liver transplantation in Spain during 1984-2012. Analysis of the Spanish Liver Transplant Registry. Med Clin (Barc). 2015;144:337-347. FI:1,267(Q2). DOI:10.1016/j.medcli.2014.07.036.

Cuervas-Mons V, Herrero JI, Gomez MA, Gonzalez-Pinto I, Serrano T, de la Mata M, et al. Impact of tacrolimus and mycophenolate mofetil regimen vs. a conventional therapy with steroids on cardiovascular risk in liver transplant patients. Clin Transplant. 2015;29:667-677. FI:1,844(Q2). DOI:10.1111/ctr.12557.

D'Avola D, Cuervas-Mons V, Marti J, Ortiz de Urbina J, Llado L, Jimenez C, et al. Long-term cardiovascular mortality after liver transplantation: analysis of risk factors. J Hepatol. 2015;62:306-307. FI:10,590(Q1). ABSTRACT

Del Hoyo I, Prieto M, Ventoso A, Valdivieso A. Giant iatrogenic hepatic hematoma with abnormal morphology. Cir Espan. 2015;93:411. FI:1,000(Q3). DOI:10.1016/j.ciresp.2015.03.004. EDITORIAL MATERIAL

Gastaca M, Andres V, Ruiz P, Ventoso A, de Urbina JO. T-tube or No T-tube in Cadaveric Orthotopic Liver Transplantation: The Type of Tube Really Matters. Ann Surg. 2015;261:172. FI:8,569(Q1). DOI:10.1097/SLA.0b013e31829d56c0.

Gastaca M, Bilbao I, Jimenez M, Bustamante J, Dopazo C, Gonzalez R, et al. Safety and efficacy of early everolimus in de novo orthotopic liver transplantation. Transpl Int. 2015;28:339. FI:2,835(Q1). ABSTRACT

Gastaca M, Bilbao I, Jimenez M, Bustamente J, Dopazo C, Gonzalez R, et al. Safety and Efficacy of Early Everolimus in De Novo Orthotopic Liver Transplantation. Am J Transplant. 2015;15:1999. FI:5,669(Q1). ABSTRACT

Gastaca M, Kataryniuk Y, Uribe-Etxebarria N, Rojo R, Ortiz de Urbina J. Thoracic involvement of hepatic hydatidosis. Surgery. 2015;157:169-170. FI:3,309(Q1). DOI:10.1016/j.surg.2013.06.049. EDITORIAL MATERIAL

Gastaca M, Prieto M, Matarranz A, Valdivieso A, Ruiz P, Ventoso A, et al. Portal Flow < 1000 cc Is Not Associated With Early Graft Dysfunction in Orthotopic Liver Transplantation. Am J Transplant. 2015;. FI:5,669(Q1). ABSTRACT

Gastaca M, Prieto P, Valdivieso A, Ortiz de Urbina J. Liver Transplantation With Aged Donors in Patients With Hepatitis C Virus. Am J Transplant. 2015;15:572. FI:5,669(Q1). DOI:10.1111/ajt.13068.

Gastaca M, Valdivieso A, Bustamante J, Ruiz P, Fernandez J, Ventoso A, et al. De Novo Once-Daily Tacrolimus in Liver Transplantation: Long-Term Outcomes of a Single Center Cohort of 150 Patients. Am J Transplant. 2015;15:1002. FI:5,669(Q1). ABSTRACT

Gastaca M, Valdivieso A, Bustamante J, Ruiz P, Fernandez JR, Ventoso A, et al. De novo once-daily tacrolimus in liver transplantation: long-term outcomes of a single center cohort of 150 patients. Transpl Int. 2015;28:199-0. FI:2,835(Q1). ABSTRACT

Jimenez M, Gastaca M, Bilbao I, Bustamante J, Dopazo C, Gonzalez R, et al. Early Everolimus in De Novo Orthotopic Liver Transplantation. Transplantation. 2015;99:213. FI:3,690(Q1). ABSTRACT

Pareja E, Cortes M, Hervas D, Mir J, Valdivieso A, Castell JV, et al. A Score Model for the Continuous Grading of Early Allograft Dysfunction Severity. Liver Transplant. 2015;21:38-46. FI:3,951(Q1). DOI:10.1002/lt.23990.

Salmeron J, Vinaixa C, Berenguer R, Pascasio JM, Sanchez JJ, Serra MA, et al. Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis. World J Gastroentero. 2015;21:9163-9174. FI:2,787(Q2). DOI:10.3748/wjg.v21.i30.9163.

Turnes J, Diaz R, Hernandez-Guerra M, Gomez M, Castells Ll, Bustamante J, et al. Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain. Gastroenterol Hepatol. 2015;38:263-273. FI:0,800(Q4). DOI:10.1016/j.gastrohep.2014.11.001.

Valdivieso A, Bustamante J, Gastaca M, Prieto M, Ruiz P, Pijoan I, et al. Recurrence of Hepatocellular Carcinoma According To Preoperative Milan Criteria After Liver Transplantation. Transplantation. 2015;99:226. FI:3,690(Q1). ABSTRACT

Valdivieso A, Prieto M, Bustamante J, Gastaca M, Ruiz P, Citores L, et al. Does an Early Liver Transplantation Influence the Prognosis of Hepatocellular Carcinoma?. Transplantation. 2015;99:163. FI:3,690(Q1). ABSTRACT

Valdivieso A, Prieto M, Gastaca M, Bustamante J, Pijoan I, Ventoso A, et al. Long Term Survival of Liver Transplantation for Hepatocellular Carcinoma Meeting Milan Criteria. Transplantation. 2015;99:237-238. FI:3,690(Q1). ABSTRACT

Bernal-Bellido C, Prieto Castillo M, Ortiz de Urbina J, Serrano T, Poyato A, Otero A, et al. Multicenter Study of Elective Liver Retransplantation in Spain. Liver Transplant. 2014;20:189. FI: 4,241(Q1)

Briceño J, Cruz-Ramírez M, Prieto M, Navasa M, Ortiz de Urbina J, Orti R, et al. Use of artificial intelligence as an innovative donor-recipient matching model for liver transplantation: Results from a multicenter Spanish study. J Hepatol. 2014;61:1020-8. FI: 11,336(Q1)

Bustamante J, Klintman D, Kriese S, Munoz Tornero M, Cadden I, McDougall N, et al. Liver Transplantation for Autoimmune Hepatitis with DCD Donors. Liver Transplant. 2014;20:190. FI: 4,241(Q1)

Buti M, Morillas RM, Pérez J, Prieto M, Solà R, Palau A, et al; ORIENTE-2 study group. Entecavir has high efficacy and safety in Caucasian patients with chronic hepatitis B and co-morbidities. J Viral Hepatitis. 2014;21:38-9. FI: 3,909(Q1)

Fabregat J, Bilbao I, Salcedo M, Gomez MA, Jimenez C, Castroagudin J, et al. Everolimus Treatment in Liver Transplantation. A Spanish Multicentre Cohort. Liver Transplant. 2014;20:246. FI: 4,241(Q1)

Gastaca M, Matarranz A, Martinez L, Valdivieso A, Ruiz P, Ventoso A, et al. Risk Factors for Biliary Complications After Orthotopic Liver Transplantation With T-Tube: A Single-Center Cohort of 743 Transplants. Transplant Proc. 2014;46:3097-9. FI: 0,982(Q3)

Gastaca M. The influence of contemporaneous revascularization on biliary complications after liver transplantation. Surgery. 2014;156:739. FI: 3,380(Q1)

Huerta I, Barasoain M, Télez M, Longa M, Muga J, Barrenetxea G, et al. Genotoxic evaluation of five Angiotesin II receptor blockers: In vivo and in vitro micronucleus assay. Mutat Res Genet Toxicol Environ Mutagen. 2014;767:1-7. FI: 2,415(Q2)

Klintman D, Bustamante J, Kriese S, Munoz Tornero M, Cadden I, McDougall N, et al. Liver Transplantation and Overlap Syndromes - A 10-Year Experience. Liver Transplant. 2014;20:343. FI: 4,241(Q1)

Klintman D, Shah N, Bustamante J, Heneghan MA. Long term follow-up and 10-year outcomes of second-line therapy in Autoimmune Hepatitis. Hepatology. 2014;60:363. FI: 11,055(Q1)

Lekerika N, Gutiérrez Rico RM, Arco Vázquez J, Prieto Molano L, Arana-Arri E, Martínez Indart L, et al. Predicting Fluid Responsiveness in Patients Undergoing Orthotopic Liver Transplantation: Effects on Intraoperative Blood Transfusion and Postoperative Complications. Transplant. Proc. 2014;46:3087-91. FI: 0,982(Q3)

Lladó L, Bustamante J; en nombre del grupo de trabajo de la Sociedad Española de Trasplante Hepático. IV Consensus Meeting of the Spanish Society of Liver Transplantation 2012. Exceptions to Model for End-stage Liver Disease in prioritizing liver transplantation. Gastroenterol Hepatol. 2014;37:83-91. FI: 0,838(Q4)

Ramia JM, Bernardo C, Valdivieso A, Dopazo C, Jover JM, Albiol MT, et al. Multicentre study on hepatic adenomas. Cir Esp. 2014;92:120-5. FI: 0,743(Q4)

Sapisochin G, de Lope CR, Gastaca M, de Urbina JO, López-Andujar R, Palacios F, et al. Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Patients Undergoing Liver Transplantation. Ann Surg. 2014;259:944-52. FI: 8,327(Q1)

Sapisochin G, Rodríguez de Lope C, Gastaca M, Ortiz de Urbina J, Suarez MA, Santoyo J, et al. `` Very Early'' Intrahepatic Cholangiocarcinoma in Cirrhotic Patients: Should Liver Transplantation Be Reconsidered in These Patients?. Am J Transplant. 2014;14:660-7. FI: 5,683(Q1)

Valdivieso A, Martinez-Indart L, Prieto M, Gastaca M, Ruiz P, Ventoso A, et al. Risk Factors of Early Arterial Complications in Liver Transplantation. Liver Transplant. 2014;20:293. FI: 4,241(Q1)

Valdivieso A, Martinez-Indart L, Prieto M, Gastaca M Ventoso A, Ruiz P, et al. Risk Factors of Late Arterial Complications in Liver Transplantation. Liver Transplant. 2014;20:220. FI: 4,241(Q1)

Marquina T, Fondevila JJ, Prieto M, Valdivieso A. Giant hydatid cyst. Nenuphar sign. Cir Esp. 2013;91:605. FI: 0,871(Q3)

Sapisochin G, Rodriguez de Lope C, Gastaca M, Ortiz  de Urbina J, Lopez  Andujar R, Palacios F, et al. Intrahepatic cholangiocarcinoma or mixed hepatocellular- cholangiocarcinoma in patients undergoing liver transplantation. A spanish matched cohort multicenter study. Transpl Int. 2013;26:4. FI: 3,155(Q1)

Prieto M, Gastaca M, Agirre L, Colina A. Randomized clinical trial of self-gripping mesh versus sutured mesh for Lichtenstein hernia repair (Br J Surg 2013; 100: 474-481). Br J Surg. 2013;100:1538. FI: 4,839(Q1)

Chizhik A, Zhukov A, Gonzalez J. Magnetic properties of sub-micrometric Fe-rich wires.Thin Solid Films. 2013;543:130-2. FI: 1,604(Q2)

Gastaca M. Temporary intraoperative porto-caval shunt: A more complete set of data is needed. Transpl Int. 2013;26:81-2. FI: 3,155(Q1)

Valdivieso N, Oteo I, Valdivieso A, Lukas JC, Leal N, Gastaca M, et al. Tacrolimus dose individualization in ``de novo'' patients after 10 years of experience in liver transplantation: pharmacokinetic considerations and patient pathophysiology. Int J Clin Pharmacol Ther. 2013;51:606-14. FI: 1,200(Q4)

Gastaca M, Andres V, Ruiz P, Ventoso A, de Urbina JO. T-tube or No T-tube in Cadaveric Orthotopic Liver Transplantation: The Type of Tube Really Matters. Ann Surg. 2013; -0. FI: 6,329(Q1)

Le Treut YP, Grégoire E, Klempnauer J, Belghiti J, Jouve E, Lerut J, et al; For ELITA. Liver Transplantation for Neuroendocrine Tumors in Europe-Results and Trends in Patient Selection A 213-Case European Liver Transplant Registry Study. Ann Surg. 2013;257:807-15. FI: 6,329(Q1)

Gastaca M, Aguero F, Peter S, Paolo G, Jueergen R, Kosh A, et al. FIPSE NIH HIVTR NEAT023. Liver Retransplantation in HIV-Infected Patients: A Multicenter and Multinational Cohort Study. Am J Transplant. 2013;13:146. FI: 6,192(Q1). (Meeting Abstract).

Rodriguez-Lope C, Sapisochin G, Gastaca M, Ortiz de Urbina J, Lopez-Andujar R, Palacios F,  et al. Intrahepatic cholangiocarcinoma (I-CC) or mixed hepatocellular-cholangiocarcinoma (HCC-CC) in patients undergoing liver transplantation. A spanish case control multicenter study. J Hepatol. 2013;58:114-5. FI: 9,858(Q1). (Meeting Abstract).

Charco R, Sapisochin G, Rodriguez-Lope C, Gastaca M, Ortiz de Urbina J, Lopez-Andujar R, et al. Intrahepatic Cholangiocarcinoma (I-CC) or Mixed Hepatocellular-Cholangiocarcinoma (HCC-CC) in Patients Undergoing Liver Transplantation (LT). Am J Transplant. 2013;13:244. FI: 6,192(Q1). (Meeting Abstract).

Sukhostavets OV, Gonzalez J, Guslienko KY. Multipole magnetostatic interactions and collective vortex excitations in dot pairs, chains, and two-dimensional arrays. Phys Rev B. 2013;87:094402. FI: 3,767(Q1)

Oteo I, Lukas JC, Leal N, Suarez E, Valdivieso A, Gastaca M, et al. Tacrolimus pharmacokinetics in the early post-liver transplantation period and clinical applicability via Bayesian prediction. Eur J Clin Pharmacol. 2013;69:65-74. FI: 2,741(Q2)

Tesis